A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

NCT00355524 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1
HIV Infections

Interventions

DRUG: TMC114
DRUG: Ritonavir

Sponsor

Tibotec Pharmaceuticals, Ireland